Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MEDACTA GROUP SA |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 113.8 CHF | -2.57% | -3.40% | +10.49% | |
| Nov. 30 | Medacta to Expand Swiss Facilities to Boost Production Capacity | MT |
| Oct. 30 | Medacta Group to Launch Optimized Knee Implant | MT |
Valuation
| Fiscal Period : December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1 334 | 1 615 | 2 743 | 2 078 | 2 403 | - | - |
| Enterprise Value (EV) 1 | 1 439 | 1 698 | 2 808 | 2 190 | 2 540 | 2 527 | 2 496 |
| P/E ratio | 113x | 43,6x | 53,2x | 45,0x | 36,0x | 29,2x | 24,3x |
| Yield | - | - | 0,39% | 0,52% | 0,59% | 0,73% | 0,88% |
| Capitalization / Revenue | 4,29x | 5,34x | 7,55x | 4,75x | 4,61x | 4,06x | 3,61x |
| EV / Revenue | 4,63x | 5,61x | 7,73x | 5,01x | 4,87x | 4,27x | 3,75x |
| EV / EBITDA | 15,7x | 19,3x | 26,2x | 18,2x | 17,7x | 15,2x | 13,1x |
| EV / FCF | 1 615x | 66,9x | 371x | 101x | 191x | 80,1x | 49,3x |
| FCF Yield | 0,06% | 1,50% | 0,27% | 0,99% | 0,52% | 1,25% | 2,03% |
| Price to Book | 10,8x | 9,80x | 12,1x | 7,56x | 7,30x | 6,06x | 5,04x |
| Nbr of stocks (in thousands) | 20 000 | 20 000 | 19 997 | 19 979 | 19 958 | - | - |
| Reference price 2 | 66,7 | 80,7 | 137 | 104 | 120 | 120 | 120 |
| Announcement Date | 06/04/20 | 30/03/21 | 11/03/22 | 17/03/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 311 | 303 | 363 | 437 | 521 | 592 | 666 |
| EBITDA 1 | - | 91,5 | 88,1 | 107 | 120 | 143 | 166 | 190 |
| EBIT 1 | - | 57,8 | 51,1 | 66,7 | 68,9 | 88,0 | 102 | 120 |
| Operating Margin | - | 18,6% | 16,9% | 18,4% | 15,8% | 16,9% | 17,3% | 18,1% |
| Earnings before Tax (EBT) 1 | - | 13,6 | 39,9 | - | 54,8 | 84,8 | 109 | 134 |
| Net income 1 | 45,8 | 11,9 | 37,1 | 51,5 | 46,2 | 66,6 | 82,0 | 98,5 |
| Net margin | - | 3,82% | 12,3% | 14,2% | 10,6% | 12,8% | 13,8% | 14,8% |
| EPS 2 | 2,29 | 0,59 | 1,85 | 2,58 | 2,31 | 3,34 | 4,12 | 4,95 |
| Free Cash Flow 1 | - | 0,89 | 25,4 | 7,57 | 21,6 | 13,3 | 31,5 | 50,7 |
| FCF margin | - | 0,29% | 8,40% | 2,08% | 4,94% | 2,55% | 5,32% | 7,61% |
| FCF Conversion (EBITDA) | - | 0,97% | 28,8% | 7,07% | 17,9% | 9,27% | 19,0% | 26,6% |
| FCF Conversion (Net income) | - | 7,51% | 68,5% | 14,7% | 46,7% | 20,0% | 38,4% | 51,4% |
| Dividend per Share 2 | - | - | - | 0,54 | 0,54 | 0,71 | 0,88 | 1,06 |
| Announcement Date | 21/03/19 | 06/04/20 | 30/03/21 | 11/03/22 | 17/03/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period : December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2023 S1 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 152 | 159 | 135 | 168 | 177 | 186 | 211 | 255 |
| EBITDA 1 | 47,0 | 44,5 | 32,1 | 56,0 | 56,6 | - | 58,1 | 71,9 |
| EBIT | 30,7 | 27,1 | 13,3 | 37,8 | 38,1 | 28,6 | - | - |
| Operating Margin | 20,3% | 17,0% | 9,86% | 22,5% | 21,4% | 15,4% | - | - |
| Earnings before Tax (EBT) 1 | 13,4 | - | - | - | - | - | - | 36,2 |
| Net income 1 | 11,3 | 0,56 | 9,68 | 27,4 | 29,7 | 21,8 | - | 29,1 |
| Net margin | 7,45% | 0,35% | 7,18% | 16,3% | 16,8% | 11,7% | - | 11,4% |
| EPS | 0,56 | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 09/03/19 | 04/06/20 | 09/07/20 | 03/30/21 | 09/10/21 | 03/11/22 | 09/09/22 | 09/21/23 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 106 | 83,3 | 65,3 | 112 | 137 | 123 | 92,2 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1,15x | 0,95x | 0,61x | 0,93x | 0,95x | 0,74x | 0,48x |
| Free Cash Flow 1 | - | 0,89 | 25,4 | 7,57 | 21,6 | 13,3 | 31,5 | 50,7 |
| ROE (net income / shareholders' equity) | - | 42,5% | 25,8% | 30,1% | 18,5% | 21,4% | 22,1% | 21,9% |
| Shareholders' equity 1 | - | 27,9 | 144 | 171 | 251 | 311 | 372 | 449 |
| ROA (Net income/ Total Assets) | - | 11,6% | 8,68% | 12,6% | 8,61% | - | - | - |
| Assets 1 | - | 102 | 427 | 409 | 537 | - | - | - |
| Book Value Per Share 2 | - | 6,16 | 8,24 | 11,3 | 13,8 | 16,5 | 19,9 | 23,9 |
| Cash Flow per Share 2 | - | - | 2,98 | 2,70 | 3,68 | 5,66 | 6,85 | 8,13 |
| Capex 1 | - | 41,5 | 34,2 | 52,0 | 63,2 | 72,1 | 77,5 | 81,1 |
| Capex / Sales | - | 13,4% | 11,3% | 14,3% | 14,4% | 13,8% | 13,1% | 12,2% |
| Announcement Date | 03/21/19 | 04/06/20 | 03/30/21 | 03/11/22 | 03/17/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
120.43EUR
Average target price
137.58EUR
Spread / Average Target
+14.24%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.49% | 2 678 M $ | |
| -4.19% | 182 B $ | |
| +2.62% | 106 B $ | |
| -6.58% | 68 780 M $ | |
| +4.42% | 45 059 M $ | |
| +22.96% | 40 616 M $ | |
| +28.30% | 39 198 M $ | |
| +49.09% | 26 029 M $ | |
| -8.32% | 24 653 M $ | |
| -23.70% | 23 949 M $ |
- Stock
- Equities
- Stock Medacta Group SA - Swiss Exchange
- Financials Medacta Group SA
